(Reuters) -Medical equipment maker Thermo Fisher is nearing an all-cash takeover of U.S-based Clario in a deal that could value the clinical trial data management company at about $10 billion, the Financial Times reported on Tuesday.
Reuters could not immediately verify the report.
The acquisition could be announced as early as Wednesday, provided the deal process does not meet any last-minute roadblocks, according to the FT report.
If finalized, the deal would mark the Massachusetts, U.S.-based company’s largest purchase since its $17.4 billion takeover of contract research firm PPD in 2021.
Thermo Fisher and Clario did not immediately respond to Reuters’ requests for a comment.
Clario, a software provider for drugmakers, was founded in 2021 from the merger of health tech firms ERT and Bioclinica. It counts private equity groups Nordic Capital and Astorg among its shareholders, according to its website.
Earlier this year, Thermo Fisher announced that it would acquire medical device maker Solventum’s purification and filtration business for about $4.1 billion.
Projecting robust demand for lab tools and benefits from its recent acquisitions, Thermo Fisher also raised its forecast for annual profit and revenue last week.
(Reporting by Ananya Palyekar in Bengaluru; Editing by Rashmi Aich and Sherry Jacob-Phillips)
Brought to you by www.srnnews.com
